LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Supernus Pharmaceuticals Inc

Open

BrancheGesundheitswesen

31.17 -0.73

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.52

Max

31.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

-27M

-12M

Verkäufe

-24M

150M

KGV

Branchendurchschnitt

29.081

50.291

EPS

0.436

Gewinnspanne

-7.894

Angestellte

674

EBITDA

-27M

18M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+25% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-345M

1.8B

Vorheriger Eröffnungskurs

31.9

Vorheriger Schlusskurs

31.17

Nachrichtenstimmung

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2025, 23:49 UTC

Ergebnisse

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. Juni 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. Juni 2025, 21:30 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. Juni 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. Juni 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. Juni 2025, 23:30 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. Juni 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. Juni 2025, 23:19 UTC

Akquisitionen, Fusionen, Übernahmen

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. Juni 2025, 22:06 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:15 UTC

Ergebnisse

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. Juni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 20:52 UTC

Ergebnisse

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. Juni 2025, 20:51 UTC

Ergebnisse

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Supernus Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

25% Vorteil

12-Monats-Prognose

Durchschnitt 39 USD  25%

Hoch 45 USD

Tief 36 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Supernus Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

1

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

31.35 / 32.36Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

154 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.